Thomas Herzog

Thomas Herzog is a gynecologic oncologist and clinical researcher at the University of Cincinnati who has contributed to defining optimal chemotherapy sequencing in platinum-resistant ovarian cancer. His clinical research addresses how prior treatment history influences outcomes with subsequent therapies and the role of bevacizumab in recurrent disease. He has been involved in cooperative group trials and has contributed to NCCN ovarian cancer guideline development. He is recognized for his educational contributions to the gynecologic oncology community.